Virtus Lifesci Biotech Clinical Trials ETF BBC

$BBC Trending higher

$BBC I’m hopeful, even if I can’t be certain.

$SLS is drawing attention as traders await the final analysis of SELLAS Life Sciences’ Phase 3 REGAL trial. 👀 Some see the wait as a hopeful sign, but the trial’s outcome remains uncertain. That’s a development to watch for holders of these four ETFs, which have exposure to $SLS at the following portfolio weights: • $ULTI: 4.96% • $SBIO: 1.48% • $BBC: 1.10% • $ETHO: 0.71%

$BBC Gap ⬆️

SLS Stock Climbs Pre-Market: CEO's Early Anniversary Post Has Retail Bulls Buzzing About Major News $SLS $XBI $BBC https://stocktwits.com/news/equity/markets/sls-stock-climbs-ceo-early-anniversary-post-has-retail-bulls-buzzing-about-major-news/cZx8nyqRBMF

YTD for $BBC (clinical-stage, no approvals) Vs $BBP (companies with at least one approved product)

$BBC gives a more accurate picture of what's been going on in bio-land of late

$CRDF $BBC is a good proxy for small cap biotechs. Look at the action since late August. Straight line down. We are caught in one of the worst biotech winters we have seen in a while. The radio silence, lack of news on both 004 and 005 would obviously provide zero support, despite the legal resolution. I am holding strong. Not adding a single share though. Management keeps disappointing, hopefully until it doesn’t. One more week to get some news, any news on how things are going. In my mind, they must be in the middle of talks for a partnership or BO. Let’s wait and see. But people saying $2BN when we are languishing at $70M market cap must be dreaming.